8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
AbbVie reports 10.2% revenue growth and agrees to acquire Apogee for $10.9 billion
Filed with the SEC on · Summarized by InvestorsBot
AbbVie reported second-quarter 2026 revenue of $16.990 billion, up 10.2% year over year, with adjusted diluted EPS of $3.65, up 22.9%; Skyrizi and Rinvoq led immunology growth, while Humira revenue fell 35.9%. The company agreed to acquire Apogee Therapeutics for approximately $10.9 billion in equity value, with closing expected in the third quarter, and lowered its 2026 adjusted EPS guidance to $13.87-$14.07 from $13.91-$14.11, including $0.14 per share of expected acquisition dilution.